Semaglutide (Semaglutide, which is also translated as a Somalug peptide and Smelumpeptide in China) is an analogy Following Essean peptide, Llauugin, Abiugide, Duraoglyce peptide, Lisa peptide, Benanugin (approved in China), the seventh GLP-1 receptor agonist in the world, It is also the third long-term long-term GLP-1 preparation in the world.
Clinical trial results
(1) Somalu peptide injection
1. The effect of hypoglycemic and weight loss is significantly better than that of placebo, Sigerine, glycry insulin U100 or slow -release Essean peptide
According to a post -analysis of the Sustain 1 ~ 5 research on the 53rd European Diabetes Research Association Annual Meeting (EASD2017) on September 12, 2017, patients with type 2 diabetes received in injection of Somalugan peptide once a week The latter hypoglycemic and weight loss effect is significantly better than that of placebo, Sigerine, glycry insulin U100 or slow -release Essean peptide.
2. “Head opposite” PK is better than ductin peptide peptide
In the “head opposite” PK of the current long-acting GLP-1 receptor excitement, Somatuman peptide also won both on the two indicators of hypoglycemic and weight loss.
3. In terms of weight loss, it is better than those of the same drug Litu peptide.
Leralugin achieved 5%weight loss effect in patients with BMI ≥ 30, and Somalugptides achieved more than 15%weight loss effect in phase II research; It shows that 1 subcutaneous injection of 0.05 ~ 0.4 mg/d under the daily subcutaneous injection. After 52 weeks of treatment and follow -up for 7 weeks, the average weight of obese patients with an average base line is 16.2%(17.8kg) and exercise。The diet combined placement group only reduced by 2.3%.
4. Cardiovascular benefit
Somalugotide is the third showing hypoglycemic drugs with cardiovascular benefits after Engelle Jing and Licolatic peptide. Compared with placebo, the risk of Somalug peptide can reduce the risk of the main composite end (the first cardiovascular death, non -fatal myocardial infarction, and non -fatal stroke) by 26%. After two years of treatment, Somalugan peptide can significantly reduce the risk of non -fatal stroke by 39%, reduce the risk of non -fatal myocardial infarction by 26%, and reduce the risk of cardiovascular death by 2%.
Post time: Apr-16-2024